ARABIAN-CHEMICAL
15.5.2024 20:34:30 CEST | Business Wire | Press release
Arabian Chemical Terminals LLC in Abu Dhabi (ACTAD) is proud to announce the start of operations at its newly built chemical tank storage terminal in Khalifa Port, Abu Dhabi, UAE. The terminal is the first commercial chemical tank farm of its kind in the Emirate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515922771/en/
ACT Abu Dhabi open for business (Photo: AETOSWire)
Strategically located in the new world class Khalifa Port and adjacent to the modern and sprawling Khalifa Economic Zone Abu Dhabi (KEZAD), ACTAD aims to participate in the drive to promote new industries in the Emirate.
ACTAD was designed and built as State of the Art in compliance with the highest international standards and boasts a total of 40 tanks of various specifications (20 Carbon Steel including 10 with IFR and 20 Stainless Steel including 10 insulated with heating/cooling system) for a total of 100,000 CBM storage capacity. Each tank has a devoted pipeline to a dedicated berth of 16 meters draft and dedicated truck loading bays, therefore, eliminating the risks of cross product contamination, promoting maximum operating efficiency and flexibility to the customers.
Additionally, the site has a 500 sqm warehouse for dangerous goods and provision for drums/IBCs filling.
The terminal has an independently operated third party fully equipped surveyor laboratory for sampling and testing.
ACTAD operates with an Integrated Management System following International Standards; ISO-9000, 14000, 18000, CDI-T and ISGOTT.
The Terminal will help local industries to import their liquid chemical needs in bulk or export their liquid chemical products to the globe. It can also act as a storage hub and/or break-bulk operations for international companies as it is strategically located in a bonded zone within Khalifa Port.
ACTAD is an extension of Arabian Chemical Terminals LTD in Saudi Arabia (ACT-KSA). ACT-KSA is an owner/operator of two other terminals, one in Yanbu on the Red Sea coast and one in Jubail Commercial Port on the Arabian Gulf. From its humble beginnings in 1986 in Yanbu, ACT-KSA was the first commercial tank farm established in Saudi Arabia, starting with 13,000 CBM of storage capacity. In 2012 ACT-KSA built the first commercial bulk storage facility in Jubail adding a further 70,000 CBM of storage capacity with tanks varying in specifications and in sizes. The Jubail terminal is currently under expansion to add a further 70,000 CBM of capacity.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515922771/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release
From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge
RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release
A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom